HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 52.78B
Enterprise Value 32.71B
Trailing P/E 43.34
Forward P/E 1-34.83
PEG Ratio (5 yr expected) 1-0.46
Price/Sales (ttm)8.77
Price/Book (mrq)13.30
Enterprise Value/Revenue 38.55
Enterprise Value/EBITDA 632.55

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2017
Most Recent Quarter (mrq)Dec 31, 2017


Profit Margin 19.89%
Operating Margin (ttm)25.58%

Management Effectiveness

Return on Assets (ttm)12.96%
Return on Equity (ttm)71.61%

Income Statement

Revenue (ttm)316.61M
Revenue Per Share (ttm)2.32
Quarterly Revenue Growth (yoy)386.00%
Gross Profit (ttm)285.46M
Net Income Avi to Common (ttm)62.97M
Diluted EPS (ttm)0.45
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)469.21M
Total Cash Per Share (mrq)3.3
Total Debt (mrq)202.35M
Total Debt/Equity (mrq)97.11
Current Ratio (mrq)3.89
Book Value Per Share (mrq)1.47

Cash Flow Statement

Operating Cash Flow (ttm)134.05M
Levered Free Cash Flow (ttm)95.69M

Trading Information

Stock Price History

Beta 3.04
52-Week Change 351.41%
S&P500 52-Week Change 312.69%
52 Week High 321.48
52 Week Low 311.41
50-Day Moving Average 319.49
200-Day Moving Average 318.38

Share Statistics

Avg Vol (3 month) 31.13M
Avg Vol (10 day) 31.09M
Shares Outstanding 5142.3M
Float 112.51M
% Held by Insiders 11.24%
% Held by Institutions 189.84%
Shares Short 312.24M
Short Ratio 310.02
Short % of Float 313.45%
Shares Short (prior month) 312.85M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A